Pieris forges discovery pact with Sanofi-Aventis
Last week Sanofi-Aventis signed on to a new discovery pact with Germany's Pieris.
Last week Sanofi-Aventis signed on to a new discovery pact with Germany's Pieris. In one of the latest signs of the Big Pharma's efforts to find more innovative ways to develop therapies with smaller players, Pieris will use its development platform to identify "Anticalins" that can hit two targets specified by Sanofi, which has an option to line up four more targets in the deal.
Pieris' Anticalins are specifically engineered lipocalins, human proteins that can naturally bind, store, and transport a spectrum of molecules. Sanofi is gambling that these Anticalins can bind to its targets and will make for better therapies than some of the antibodies which have taken center stage in the biotech world.
"Our molecules are monovalent as opposed to bi-valent," Pieris CEO Stephen Yoder tells FierceBiotechResearch. By overcoming some of the limitations of antibodies, Pieris and Sanofi believe that the technology can deliver novel therapies that can zero in on their targets, imp
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance